Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Methotrexate use in systemic lupus erythematosus

Y Kipen1, G O Littlejohn, E F Morand

  • 1Rheumatology Unit, Monash Medical Centre, Melbourne, Victoria, Australia.

Lupus
|January 1, 1997
PubMed
Summary

Methotrexate (MTX) shows good long-term tolerability in Systemic Lupus Erythematosus (SLE) patients, primarily for arthritis. While MTX treatment is often maintained, significant steroid dose reduction was not consistently observed.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Urinary B-cell-activating factor of the tumour necrosis factor family (BAFF) in systemic lupus erythematosus.

Lupus·2018
Same author

Longitudinal association of type 1 interferon-induced chemokines with disease activity in systemic lupus erythematosus.

Scientific reports·2018
Same author

Discordance of patient and physician health status concerns in systemic lupus erythematosus.

Lupus·2017
Same author

Validation of the Lupus Impact Tracker in an Australian patient cohort.

Lupus·2016
Same author

Association of MIF, but not type I interferon-induced chemokines, with increased disease activity in Asian patients with systemic lupus erythematosus.

Scientific reports·2016
Same author

Fibromyalgia onset has a high impact on work ability in Australians.

Internal medicine journal·2016

Area of Science:

  • Rheumatology
  • Immunology
  • Pharmacology

Background:

  • Methotrexate (MTX) is established for rheumatoid arthritis.
  • Short-term studies suggest MTX benefits in Systemic Lupus Erythematosus (SLE).

Purpose of the Study:

  • To evaluate MTX treatment maintenance rates in SLE patients.
  • To determine if MTX use correlates with reduced steroid dosage.

Main Methods:

  • Cross-sectional study of SLE patients.
  • Life table analysis of MTX treatment duration and Kaplan-Meier methods for drug data.
  • Data collected via interviews and chart reviews.

Main Results:

  • 101 SLE patients studied, with 25 MTX treatment episodes observed.
  • Median MTX treatment duration was 14.4 months; 68% continued treatment at 12 months.
  • Arthritis was the main indication; remission was the primary reason for discontinuation, not toxicity.
  • No significant reduction in steroid dose was observed during MTX therapy, though some patients reduced intake.

Conclusions:

  • Long-term MTX treatment for SLE, mainly for arthritis, is well-tolerated.
  • Treatment discontinuation due to MTX toxicity is rare.
  • While some SLE patients may reduce steroid doses during MTX therapy, this is not a universal outcome.

Related Experiment Videos